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Abstract
Background Despite extensive translational research, no
validated biomarkers predictive of bevacizumab treatment
outcome have been identified.
Methods We performed a meta-analysis of individual
patient data from six randomized phase III trials in colo-
rectal, pancreatic, lung, renal, breast, and gastric cancer to
explore the potential relationships between 195 common
genetic variants in the vascular endothelial growth factor
(VEGF) pathway and bevacizumab treatment outcome.
Results The analysis included 1,402 patients (716 bev-
acizumab-treated and 686 placebo-treated). Twenty vari-
ants were associated (P \ 0.05) with progression-free
survival (PFS) in bevacizumab-treated patients. Of these, 4
variants in EPAS1 survived correction for multiple testing
(q \ 0.05). Genotype-by-treatment interaction tests
revealed that, across these 20 variants, 3 variants in VEGF-
C (rs12510099), EPAS1 (rs4953344), and IL8RA
(rs2234671) were potentially predictive (P \ 0.05), but not
resistant to multiple testing (q [ 0.05). A weak genotype-
by-treatment interaction effect was also observed for
rs699946 in VEGF-A, whereas Bayesian genewise analysis
revealed that genetic variability in VHL was associated
with PFS in the bevacizumab arm (q \ 0.05). Variants in
VEGF-A, EPAS1, and VHL were located in expression
quantitative loci derived from lymphoblastoid cell lines,
indicating that they affect the expression levels of their
respective gene.
Conclusions This large genetic analysis suggests that
variants in VEGF-A, EPAS1, IL8RA, VHL, and VEGF-
C have potential value in predicting bevacizumab treatment
outcome across tumor types. Although these associations
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did not survive correction for multiple testing in a geno-
type-by-interaction analysis, they are among the strongest
predictive effects reported to date for genetic variants and
bevacizumab efficacy.
Keywords Anti-angiogenesis  Bevacizumab  Treatment
outcome  Genetic variant  Predictive and prognostic
biomarker
Introduction
Bevacizumab, a humanized monoclonal antibody that binds
to vascular endothelial growth factor (VEGF), was the first
anti-VEGF-specific drug to be approved in the clinic. The
addition of bevacizumab to standard therapy has been shown
to significantly improve outcome in patients with metastatic
colorectal [1], non-small cell lung [2], breast [3–5], renal [6],
and ovarian [7–9] cancer, and recurrent glioblastoma [10].
Although anti-angiogenic drugs have changed clinical
practice in several cancers, various clinical challenges
remain [11]. For instance, after initial response, adaptive
escape mechanisms ultimately lead to disease progression in
most patients [12, 13]. There is remarkable heterogeneity in
the timing of angiogenic escape, with some patients relaps-
ing almost immediately and others having prolonged periods
of stabilized disease [14]. A current challenge, therefore, is to
identify and validate markers predictive of bevacizumab
treatment outcome. Despite concerted efforts using a broad
spectrum of biological sample types [15–17], a validated
marker predictive of treatment outcome for bevacizumab
therapy has not been identified so far.
As host factors may influence angiogenesis, it is plau-
sible that genetic variability may underlie differences in
response to bevacizumab. The characterization of common
genetic variability therefore represents a logical focus in
bevacizumab biomarker research. Various potential pre-
dictive genetic markers have been identified in clinical
trials evaluating bevacizumab in several tumor types [18–
26] but these analyses, generally using single-trial datasets,
are limited by the number of available samples, heteroge-
neity in the selection of single-nucleotide polymorphisms
(SNPs), and lack of understanding of the functional con-
sequences of these genetic markers.
The aim of this study was to identify genetic variants
associated with bevacizumab treatment outcome in patients
with advanced cancer regardless of tumor type. Although it
is not yet clear to what extent markers predictive of
treatment response are shared between cancer types, a clear
advantage of such an approach is that patients participating
in various phase III clinical trials can be combined and
much larger patient numbers can be assessed. Here, we
pooled patients from six clinical studies in breast,
colorectal, pancreatic, gastric, lung, and renal cancers,
thereby performing the largest genetic study to date aiming
to predict bevacizumab efficacy.
Patients and methods
Patient population
The analysis included samples from patients treated in six
randomized phase III trials of bevacizumab in colorectal
cancer (NO16966), pancreatic cancer (BO17706; AViTA),
advanced or recurrent non-squamous non-small cell lung
cancer (BO17704; AVAiL), metastatic renal cell cancer
(BO17705; AVOREN), HER2-negative metastatic breast
cancer (BO17708; AVADO), and advanced gastric cancer
(BO20904; AVAGAST). The designs and primary clinical
results (efficacy and safety) for these trials have been
published previously [1, 4, 6, 27–29]. Four of the trials met
their primary objectives of improving overall survival (OS)
and/or progression-free survival (PFS). However, although
AViTA and AVAGAST demonstrated improved PFS
(secondary end point), the primary end point of OS in these
trials did not improve with the addition of bevacizumab to
standard chemotherapy. As expected, owing to the fact that
different tumor types were assessed, median values and
censoring rates for PFS and OS varied considerably
between the trials (Table 1).
The genetic analyses were performed on a subset of
patients who consented to participate in a genetic substudy,
donated a blood sample from which DNA could be suc-
cessfully extracted and genotyped, and self-reported
‘‘white’’ ethnicity (with the aim of limiting false positives
by using an ethnically homogeneous patient population).
Laboratory methods
Peripheral blood samples were collected in K2EDTA
Vacutainer tubes (BD, Franklin Lakes, NJ, USA). Germ
line DNA was extracted from the precipitated leukocyte
cell fraction. Genotyping was performed at the Vesalius
Research Center, Leuven, Belgium, with MassARRAY
iPLEX Gold (Sequenom, San Diego, CA, USA), as
reported previously [23].
We selected SNPs in the following 15 genes involved in
the VEGF-A pathway: VEGF-A, the VEGF-A homologs
[placental growth factor (PlGF), VEGF-B, VEGF-C, and
VEGF-D (also known as c-fos-induced growth factor or
FIGF)], VEGF receptor-1 (VEGFR-1 or FLT1), VEGF
receptor-2 (VEGFR-2 or KDR) and VEGF receptor-3
(VEGFR-3 or FLT4), regulators of hypoxia [hypoxia
inducible factor-1a (HIF1A), HIF-2a (EPAS1), factor
inhibiting HIF-1A (FIH1), von Hippel–Lindau tumor
910 Angiogenesis (2014) 17:909–920
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suppressor (VHL)], and the oxygen sensors [prolyl
hydroxylase domain-containing protein 1 (EGLN2), 2
(EGLN1), and 3 (EGLN3)]. A detailed description of how
SNPs were selected in these genes has been published
previously [23]. Briefly, genomic sequences 5 kb upstream
of the translation start site and downstream of the 30 poly-
adenylation site of each gene were used to select SNPs
from the HapMap database (Phase 2 Public release number
22). Common SNPs with a minor allele frequency C0.1
and pairwise correlation coefficients (r2) B0.8 were
selected using the SNP Tagger approach of the Haploview
software package [30, 31]. Overall, we selected 211 tag-
ging SNPs in these VEGF pathway genes, as well as 10
genetic variants previously associated with bevacizumab
efficacy. Fifteen SNPs known to increase patients’ sus-
ceptibility to hypertension and thrombosis were also
included. These were not analyzed for their effect on
bevacizumab treatment outcome, but for correlation with
bevacizumab-induced hypertension; results were published
recently [32]. After testing for minor allele frequency and
the homogeneity of the observed allele frequency (Sup-
plementary Fig. 1), 195 SNPs were included in the analysis
(Supplementary Table 1).
Circulating VEGF-A and VEGF-C concentrations were
measured in plasma collected from 119 healthy individuals
with self-reported Flemish ethnicity for three generations
using Human Quantikine ELISA kits (R&D Systems)
according to the manufacturer’s instructions. Expression
and genotype data of 856 lymphoblastoid cell lines derived
from healthy female twins of the MuTHER study [33] were
used to assess SNP–gene associations in expression quan-
titative loci (eQTLs) using the Genevar [34] platform.
Statistical methods
Individual patient data were pooled for the meta-analysis.
Potential correlations between markers and clinical out-
come were assessed in the subset of bevacizumab-treated
patients, the subset of placebo-treated patients, and in all
patients irrespective of treatment. The end point of primary
interest was PFS; OS was a secondary end point. Four
covariates were pre-specified for these analyses: geo-
graphic region, study, bevacizumab dose, and chemother-
apy backbone. Backwards stepwise regression identified
additional covariates: Eastern Cooperative Oncology
Group (ECOG) performance status (0 vs. 1/2), lactate
dehydrogenase level (normal vs. abnormal), baseline
serum albumin level (B29 vs. [29 g/L), and baseline
number of lesions (B2 vs. [2) for PFS and OS. For OS,
two additional covariates were identified: alkaline phos-
phatase level (B2.5 vs.[2.5 9 upper limit of normal) and
gender.T
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For the single-marker analyses, 195 genetic markers
were first tested for single-point association with bev-
acizumab treatment effect using Cox proportional hazards
regression within the subset of patients treated with bev-
acizumab. Results were then compared with tests of asso-
ciation in the subset of patients not treated with
bevacizumab. Genotype-by-treatment interactions were
used in the full set to formally test the potential predictive
value of candidate markers. Prognostic characteristics were
evaluated using tests of association in the full dataset. False
discovery rate (FDR) q values were computed to correct for
multiple testing, reflecting the exploratory nature of these
analyses [35].
For the genewise analysis, associations were tested on a
gene-by-gene basis using an empirical Bayesian general-
ized linear model [36, 37]. This method was originally
developed to allow the joint analysis of data from multiple
functionally related genes in microarray data, and was
implemented to jointly analyze multiple markers from a
single gene. The method takes into account the different
group sizes, i.e., the different numbers of variants tested in
each gene (e.g., [30 variants tested in EPAS1 vs. 2 or 3
markers tested in most other genes). The implemented
method used is available in the R-package as the globaltest.
Elastic net analysis was applied to evaluate potential
prognostic or predictive effects of marker combinations. A
subset of 141 candidate markers with \10 % missing data
was subjected to elastic net variable selection [38–40].
Elastic net analysis differs from the above analyses as it
allows simultaneous analysis of clinical covariates and
markers, thereby identifying the best statistical predictors
for a given trait. It encompasses a penalized regression
approach that carries advantages of both ridge and lasso
penalties, such that it provides shrinkage and variable
selection with efficient handling of highly correlated vari-
ables (multi-collinearity). Missing genotypes were imputed
to the heterozygote genotype (the mode); all variables were
standardized, and tuning parameters were selected by two-
dimensional tenfold cross-validation. In the interests of
sparsity, the partial likelihood deviance was allowed to
increase to its highest level such that prediction error was
within one standard deviation of the minimum. To obtain a
robust estimate of the multivariate model performance, all
patients (irrespective of treatment) were stratified by study
and randomized to a training or validation set. Elastic net
analysis was performed on the training set, and the iden-
tified variables were combined into a single continuous
classification signature based on the Cox proportional
hazards model. The performance of the model was tested
using the validation set. Patients were classified into two
groups based on the median of the signature, and the two
patient subgroups were compared using Kaplan–Meier
estimates.
Results
Patient population
The subset of patients included in this genetic substudy
comprised 1,402 patients: 716 randomized to bevacizumab
and 686 randomized to placebo (Table 1). Only patients
who self-reported ‘‘white’’ ethnicity were included in the
analysis. Notably, only 60 % of patients participating in the
AVAGAST (BO20904) study were from Western Europe,
Australia, or North America, whereas in the remaining 5
trials, 88 % of patients were from Western Europe, Aus-
tralia, or North America, 10 % were from Eastern Europe,
and 2 % were from the rest of the world.
Single-marker analyses
Of the 195 variants tested, 20 were associated with PFS in
bevacizumab-treated patients at an unadjusted P \ 0.05
(Table 2; variants are shown in descending order of asso-
ciation strength). Data for all 195 variants tested are listed
in Supplementary Table 1. The strongest associations with
PFS were seen for variants in EPAS1 and VEGF-A (12 out
of 34 EPAS1 variants and 4 out of 15 VEGF-A variants had
a P \ 0.05). The remaining associations were in 2 VHL
variants, 1 VEGF-C and 1 IL8RA variant. Notably, 4
variants in EPAS1 (rs4145836, rs11689649, rs7594278,
and rs1374749), of which rs4145836 was most significantly
associated with PFS [hazard ratio (HR) 0.69; 95 % confi-
dence interval (CI) 0.58–0.83; P = 0.0001], also survived
correction for multiple testing (q \ 0.05 using FDR
correction).
Genotype-by-treatment interaction tests indicated a
potential predictive effect for 3 of these 20 variants:
rs12510099 in VEGF-C (interaction P = 0.0311),
rs4953344 in EPAS1 (interaction P = 0.0454), and
rs2234671 in IL8RA (interaction P = 0.0492). None of
these SNPs survived correction for multiple testing
(q [ 0.05). Kaplan–Meier curves for these individual SNPs
are shown in Fig. 1. Forest plots displaying HRs in the
individual studies are presented in Fig. 2. One additional
variant (rs699946 in the VEGF-A promoter) showed a trend
toward a potential predictive interaction effect (interaction
P = 0.0907; Table 2). The allelic HR for this SNP was
1.27 (95 % CI 1.08–1.49; P = 0.0034), whereas no effect
was seen in placebo-treated patients (P = 0.9110). The
nearby rs699947 SNP in VEGF-A, which was previously
identified as a predictor of bevacizumab treatment outcome
in the E2100 trial in breast cancer [20], was not associated
with bevacizumab treatment outcome in our analysis.
Although our primary end point of interest was PFS,
similar analyses were performed for the secondary end
point, OS. Eight of the 195 variants showed a potential
912 Angiogenesis (2014) 17:909–920
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association (P \ 0.05) with OS in bevacizumab-treated
patients (Supplementary Table 2). Three of these variants
were located in VEGFR-1 (FLT1). The most distinct
association (HR 1.41, 95 % CI 1.15–1.72; P = 0.001) was
for rs12505758, which is one of the 26 VEGFR-2 (KDR)
variants tested. However, none of the 8 variants surpassed
FDR correction. Genotype-by-treatment interaction tests
suggested a potential predictive effect on OS for rs7987649
in VEGFR-1 (interaction P = 0.0062) and rs12505758 in
VEGFR-2 (interaction P = 0.0165; Supplementary
Table 2).
We also assessed the effect of these 195 variants on PFS
irrespective of treatment arm. Analysis of PFS data col-
lected from all 1,402 patients treated with either bev-
acizumab or placebo revealed 25 variants exhibiting
P \ 0.05. Twelve of these variants were located in EPAS1
(Supplementary Table 3). Similar to the bevacizumab-
treated arm, rs4145836 in EPAS1 was most significantly
associated with PFS (Fig. 3a; allelic HR 0.74; 95 % CI
0.65–0.84; P = 2.2 9 10-6) and survived correction for
multiple testing. In 5 of 6 trials, the HRs for rs4145836
consistently pointed in the same direction, indicating that
the prognostic effect of rs4145836 was consistent across
tumor types (Fig. 3b). Overall, 5 markers in EPAS1
(rs4145836, rs6712143, rs6715787, rs1562452, and
rs7594278) were associated with PFS after correcting for
multiple testing (q \ 0.05 using FDR correction). Similar
analyses for OS in all 1,402 patients revealed that 15 out of
195 variants were associated with OS at P \ 0.05. Six of
these were in EPAS1, but none of them surpassed the
multiple testing threshold. Notably, the association
between rs4145836 in EPAS1 and OS (HR 0.81; 95 % CI
0.71–0.94; P = 0.0045) was in the same direction as
observed for PFS.
Genewise analyses and elastic net analyses
Next, we complemented these single-variant analyses with
a Bayesian genewise association analysis for PFS. By
considering all variants located in a specific gene simul-
taneously, this analysis explored whether the combined
effects of individual variants were associated with PFS
either in the bevacizumab-treated group or in the overall
patient population. Eighteen genes containing 2 or more
variants were considered for this analysis. After correction
for multiple testing using the FDR approach, 2 genes were
associated with PFS (q \ 0.05) in the bevacizumab arm:
EPAS1 (34 variants) and VHL (2 variants). In the entire
population of 1,402 patients, only EPAS1 had an FDR-
adjusted q \ 0.05 for PFS. In a similar genewise analysis
Table 2 Markers with P \ 0.05 in association testing of 195 markers against PFS in white patients receiving bevacizumab, with corresponding
data in placebo-treated patients. The four variants with the lowest genotype-by-treatment interaction P-value (P \ 0.1) are marked in bold
Marker Chr All white Bevacizumab Placebo Genotype-by-
treatment interaction P
Gene
Position MAF HWE P N HR 95 % CI P value P value
rs4145836 2 46595363 0.13 0.96 641 0.69 0.58–0.83 1.00E-04 0.0059 0.7874 EPAS1
rs11689649 2 46617118 0.50 0.79 485 1.28 1.12–1.47 3.00E-04 0.5098 0.1521 EPAS1
rs7594278 2 46604593 0.47 0.61 656 1.22 1.09–1.37 6.00E-04 0.1320 0.3731 EPAS1
rs1374749 2 46596433 0.48 0.56 660 0.82 0.73–0.92 8.00E-04 0.3062 0.1659 EPAS1
rs6753127 2 46597296 0.08 0.06 661 0.73 0.59–0.89 0.0025 0.3337 0.2381 EPAS1
rs3768730 2 46592524 0.47 0.80 463 1.25 1.08–1.44 0.0028 0.2831 0.4392 EPAS1
rs699946 6 43732669 0.18 0.30 542 1.27 1.08–1.49 0.0034 0.9110 0.0907 VEGF-A
rs1678607 3 10188428 0.13 0.28 659 0.78 0.66–0.93 0.0051 0.2200 0.4150 VHL
rs833058 6 43731854 0.37 0.88 660 1.18 1.05–1.32 0.0053 0.5404 0.2328 VEGF-A
rs7565341 2 46599030 0.41 0.31 654 0.85 0.76–0.95 0.0055 0.3361 0.2804 EPAS1
rs12510099 4 177602953 0.09 0.94 643 0.73 0.58–0.91 0.0060 0.9266 0.0311 VEGF-C
rs3025030 6 43750587 0.14 0.12 636 1.22 1.04–1.43 0.0124 0.4816 0.4143 VEGF-A
rs3025039 6 43752536 0.15 0.31 703 1.21 1.04–1.40 0.0135 0.8285 0.2277 VEGF-A
rs2881324 2 46576894 0.49 0.27 327 0.82 0.69–0.96 0.0153 0.1234 0.8957 EPAS1
rs1562452 2 46580444 0.50 0.59 661 0.87 0.77–0.97 0.0155 0.0232 0.8606 EPAS1
rs1642742 3 10191943 0.32 0.55 650 0.86 0.77–0.97 0.0163 0.9199 0.1540 VHL
rs4953344 2 46552458 0.16 0.43 640 0.83 0.71–0.97 0.0165 0.4763 0.0454 EPAS1
rs13409493 2 46588488 0.12 0.59 587 0.82 0.68–0.98 0.0338 0.5773 0.3727 EPAS1
rs2234671 2 219029108 0.05 0.28 695 1.33 1.02–1.73 0.0376 0.4303 0.0492 IL8RA
rs2121267 2 46549389 0.45 0.77 661 1.13 1.01–1.26 0.0381 0.8354 0.2354 EPAS1
Chr chromosome, CI confidence interval, N number of patients, MAF minor allele frequency, HR hazard ratio, HWE P Hardy–Weinberg P value
Angiogenesis (2014) 17:909–920 913
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Fig. 1 Kaplan–Meier curves
for progression-free survival
stratified by treatment arm and
single-nucleotide
polymorphisms. a rs12510099
in VEGF-C, b rs4953344 in
EPAS1, c rs2234671 in IL8RA,
and d rs699946 in VEGF-A
(a) (b)
(c) (d)
Fig. 2 Forest plots showing the
association of progression-free
survival with a rs12510099 in
VEGF-C, b rs4953344 in
EPAS1, c rs2234671 in IL8RA,
and d rs699946 in VEGF-
A. CRC colorectal cancer, BC
breast cancer, GC gastric
cancer, RCC renal cell cancer,
PC pancreatic cancer, NSCLC
non-squamous non-small cell
lung cancer
914 Angiogenesis (2014) 17:909–920
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for OS, none of the genes had an FDR-adjusted q \ 0.05
for OS in either the bevacizumab-treated subset or the
combination of both treatment arms.
Given the consistent prognostic effect of EPAS1 variants
observed in the univariate and genewise analyses, a mul-
tivariate elastic net analysis was undertaken to identify a
combination of genetic and clinical variables prognostic for
clinical outcome. With respect to PFS, 4 clinical covariates
(region, concomitant gemcitabine, ECOG performance
status, and trial) and two genetic variants [rs4145836 in
EPAS1 and rs3034659, the ?4422(AC)11-14 repeat in
VEGFR-2] were identified as a signature in the training set
(Supplementary Table 4a). Figure 4a shows the Kaplan–
Meier curve in the validation set when classified by the
median of this signature. The HR comparing the ‘‘above
median’’ versus ‘‘below median’’ subgroups revealed a
substantial and significant difference in the overall popu-
lation (HR 0.57; 95 % CI 0.48–0.67; P = 2.9 9 10-12)
and within both individual treatment arms (bevacizumab:
HR 0.59; 95 % CI 0.47–0.73; P = 2.2 9 10-6; placebo:
HR 0.54; 95 % CI 0.43–0.68; P = 1.4 9 10-7). The
performance of the PFS signature was also investigated
with respect to OS in the validation set (Fig. 4b) and
demonstrated a similar strong effect (HR 0.43; 95 %CI
0.36–0.52).
When using the elastic net analysis for the identification
of predictors for OS, 9 clinical covariates were identified in
the training set as well as 8 genetic variants (rs1042886 in
PlGF, rs12888409 in HIF-1A, rs1870377 and rs2125489 in
VEGFR-2, rs2281827 and rs9508021 in VEGFR-1, and
rs4145836 and rs9973653 in EPAS1; Supplementary
Table 4b). Notably, bevacizumab treatment was again not
identified as one of the 9 clinical covariates. When this OS
signature was evaluated in the validation set, the HR for
OS comparing above versus below the median was sub-
stantial and significant (HR 0.38; 95 % CI 0.32–0.46;
P \ 2 9 10-16; Supplementary Fig. 2). The performance
of the OS signature was also investigated with respect to
PFS in the validation set and showed a similarly strong
effect (HR 0.52; 95 % CI 0.44–0.60; P = 3.3 9 10-16).
Functional effects of variants predictive
of bevacizumab outcome
To test whether any of these significant SNPs also affect
mRNA expression of their respective genes, we assessed
whether they were located in expression quantitative trait
loci (eQTL), as identified by Genevar [34]. Using mRNA
expression data from 856 lymphoblastoid cell lines [33],
we confirmed that rs699946 in VEGF-A was located in an
eQTL (P = 0.0161; Fig. 5a). In particular, rs699946 AA
carriers exhibited a 6 and 12 % reduction in mRNA
expression compared to, respectively, rs699946 GA and
GG carriers. In contrast, rs2234671 and rs12510099 were
not located in an eQTL associated from IL8RA or VEGF-
C. Several of the EPAS1 SNPs did, however, locate in an
eQTL from EPAS1. In particular, although the predictive
rs4953344 variant in EPAS1 itself was not genotyped, the
SNP with the highest r2 value to rs4953344, i.e.,
rs3768727, was significantly associated with EPAS1
expression (P = 0.0437; Fig. 5b). Also, the minor
rs13409493 T-allele, which was predictive in the meta-
analysis and correlated with improved PFS (Table 2), was
significantly associated with increased EPAS1 mRNA
expression (P = 0.0326; Fig. 5b), whereas the rs4145836
variant, which was associated with a prognostic effect, was
not in an EPAS1 eQTL. On the other hand, we confirmed
that rs1678607 and rs1642742 in VHL were both located in
an eQTL significantly determining VHL mRNA expression
(P = 4.77 9 10-8 and P = 2.58 9 10-4, respectively;
Fig. 5c). In particular, minor alleles of both SNPs strongly
correlated with increased VHL mRNA expression.
We observed a similar correlation between rs699946
and circulating plasma VEGF-A concentration in healthy
(a)
(b)
Fig. 3 a Kaplan–Meier curves for progression-free survival stratified
by treatment arm and rs4145836 genotypes. b Forest plot showing the
association of rs4145836 in EPAS1 with progression-free survival.
CRC colorectal cancer, BC breast cancer, GC gastric cancer, RCC
renal cell cancer, PC pancreatic cancer, NSCLC non-squamous non-
small cell lung cancer
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(a) (b)
Fig. 4 Kaplan–Meier curves in the validation set classified based on the median of the signature for a PFS and b OS. The model was derived for
PFS in a training set comprising half of the bevacizumab-treated and half of the placebo-treated patients
(a) (b)
(c) (d)
Fig. 5 Regional plots from the
eQTL analysis in 856
lymphoblastoid cell lines of
healthy female twins of the
MuTHER study for a VEGF-A,
b EPAS1, and c VHL. On the X-
axis, the chromosomal positions
of the SNPs are shown; on the
Y-axis, the -log10 P value
obtained for the eQTL analysis
between the SNPs against
mRNA expression of their
respective genes is shown.
Variants identified in this study,
or their closest proxies
genotyped in the MuTHER
study, are indicated in the
individual plots. d The
correlation of VEGF plasma
levels with SNP rs699946
genotypes. BEV bevacizumab,
OS overall survival, PFS
progression-free survival, PLA
placebo
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individuals (P = 0.006; Fig. 5d) but not between
rs12510099 and plasma VEGF-C concentration. EPAS1,
VHL, and IL8RA were not detectable in plasma as these
proteins are intracellular or membrane-bound.
Discussion
The most significant finding of this study is the identifi-
cation of 3 genetic variants in VEGF-C, EPAS1, and IL8RA
that were predictive of bevacizumab treatment outcome.
The effects of these variants were significant (P \ 0.05)
when assessing PFS in bevacizumab-treated patients only,
as well as in a genotype-by-treatment interaction analysis.
One additional variant in VEGF-A was also predictive in
bevacizumab-treated patients but failed to reach signifi-
cance in the interaction analysis (P = 0.091). This variant
could nevertheless be considered as an additional variant
potentially predictive of bevacizumab treatment outcome,
as it significantly affected VEGF expression. Two variants,
rs12505758 in VEGFR-2 and rs7987649 in VEGFR-1, were
also predictive for OS. The interpretation of OS data was,
however, more difficult as crossover events might have
affected the OS analysis. It should be noted that none of the
treatment-by-interaction effects for PFS or OS remained
statistically significant after FDR correction for testing 195
variants. Replication in additional studies is therefore
needed before considering these markers as true predictors
of bevacizumab treatment outcome across tumor types.
A correlation between rs2234671 in IL8RA (CXCR1)
and treatment outcome has previously been described in a
single-arm study of 132 patients receiving bevacizumab for
colorectal cancer [22]. Wild-type CC carriers were char-
acterized by increased response rates and prolonged PFS.
In our much larger cohort of 716 bevacizumab-treated
patients, similar effects on PFS were noticed, but impor-
tantly, rs2234671 was also significant in the treatment-by-
interaction analysis including 686 patients receiving pla-
cebo. The rs2234671 variant represents a non-synonymous
SNP in exon 1 of CXCR1, which tags a large linkage dis-
equilibrium block across CXCR1. Although rs2234671 did
not correlate with altered CXCR1 mRNA expression in
Genevar, it might still reduce IL8 signaling at the protein
level by introducing an amino acid substitution (S276T) at
a conserved position. Notably, altered expression of
CXCR1 has previously been reported to regulate angio-
genesis independently of VEGF-A and to activate a tumor-
specific immune response by attracting leukocytes, poten-
tially suggesting mechanisms by which this variant might
affect bevacizumab treatment outcome [41].
The rs699946 variant, which is located in the VEGF-
A promoter, was previously identified as a marker of
treatment outcome in patients receiving bevacizumab for
neovascular age-related macular degeneration [42]. In the
present study, AA carriers of rs699946 exhibited an
improved PFS after bevacizumab treatment compared with
placebo-treated patients. When stratifying VEGF plasma
concentrations from healthy subjects according to
rs699946, we noticed that VEGF concentrations were
lower in AA than GG carriers, an effect that was confirmed
at the mRNA level in Genevar. On the other hand,
rs12510099 in VEGF-C has not yet been studied and since
it did also not affect VEGF-C expression, its role in pre-
dicting bevacizumab treatment outcome is currently
unclear. Finally, we also identified 2 variants in VHL that
were associated with bevacizumab treatment outcome at
P \ 0.05. In the genewise analysis, the combined effects of
both these variants were significant even at an FDR-
adjusted q \ 0.05 for PFS. Minor alleles of both variants
also correlated with increased VHL mRNA expression in
Genevar and were associated with improved PFS after
bevacizumab.
Another intriguing finding is that, although several
variants in EPAS1 were significant (P \ 0.05) when
assessing PFS in bevacizumab-treated patients only, one
variant in EPAS1 exerted a strong prognostic rather than
predictive effect on PFS. The prognostic effect of the
rs4145836 variant resisted correction for multiple testing
and was also retrieved in the multivariate signature iden-
tified by elastic net analyses. EPAS1 (or HIF-2a) is an
oxygen-sensitive transcription factor that allows adaptation
of cells to hypoxic environments [43]. It has a well-
established role during angiogenesis [44–46], but recent
evidence also implicates this gene as a key mediator of the
metabolic adaption of tumors and the infiltration of
inflammatory cells into the tumor microenvironment [47].
Previous studies revealed, for instance, that EPAS1, as
assessed by immunohistochemistry, is present at increased
levels in some tumors and that these patients have signif-
icantly decreased survival compared with patients whose
tumor samples have undetectable levels of EPAS1 [48].
Furthermore, EPAS1 expression appears to be upregulated
in the surrounding stroma, in particular in tumor-associated
macrophages, as opposed to the tumor cells [49]. These
elevated expression levels of EPAS1 in tumor-associated
macrophages correspond directly with clinical severity of
many different human cancers [50]. Interestingly, several
genome-wide studies conducted in populations biologically
adapted to living at high altitude, such as the Tibetan
population, revealed EPAS1 variants that were under strong
genetic selection and responsible for high-altitude adapta-
tions [51–53]. Some of the variants identified in the present
study were in high linkage disequilibrium with these
variants supporting the notion that they affect EPAS1
expression or function. Genevar analysis indeed confirmed
that several of these SNPs were highly significantly
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correlated with EPAS1 mRNA expression levels. Addi-
tional fine-mapping studies should be conducted to identify
the causal variant(s) in EPAS1 contributing to these phe-
notypes. With respect to the latter, carriers of EPAS1
genotypes that correlated increased EPAS1 expression
exhibited prolonged PFS.
Finally, using elastic net analyses to identify genetic
variants and clinical variables significantly contributing to
clinical outcome, we observed that bevacizumab treatment
did not significantly contribute to the regression model,
whereas, surprisingly, several of the genetic variants did
contribute. The lack of an association with bevacizumab
treatment can probably be explained by the fact that bev-
acizumab exerts very minimal therapeutic effects in some
of the cancer types included in the meta-analysis, whereas,
on the other hand, the fact that variants in angiogenesis-
related genes were identified as prognostic factors across
various cancer types is noteworthy.
With respect to the statistical analysis, we chose to apply
a pooled meta-analysis of individual patient data rather
than a random-effects meta-analysis. Although the latter
model is intuitively appealing, there were insufficient
clinical studies to precisely model the between-studies
variance. Another potential weakness of the study is the
lack of a replication set. We decided, however, to combine
all available data into a single analysis to maximize sta-
tistical power. Moreover, in the case of the association
between PFS and rs4145836, the effect size estimated from
pooling individual patient data was HR 0.74, very close to
that derived from the fixed-effects meta-analysis of sum-
mary statistics (HR 0.75), suggesting that the association
was not attributable to patient stratification. Finally, since
we selected 195 variants that were in low LD with each
other, we did not perform a haplotype-based analysis, as
has previously been performed, for instance, for the VEGF-
A promoter [54, 55].
In conclusion, by performing a meta-analysis of indi-
vidual data from more than 1,400 patients across 6 dif-
ferent tumor types, we identified several potentially
predictive markers of bevacizumab treatment outcome that
also functionally affected the expression levels of their
target genes. We anticipate that these findings will con-
tribute to ongoing efforts aimed at identifying markers that
predict which patients will benefit most from bevacizumab
therapy.
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